Nautilus Biotechnology, Inc. - 10-Q Filing
Nautilus Biotechnology reports Q3 2026 financial results with focus on grant and service revenue segments.
Tickers: $NAUT
Read the full article at SEC EDGAR
Part of the story UPS Exceeds Third Quarter Estimates Driven by Network Efficiency and Revenue Growth (11 articles)